Antibody-targeted nanovectors for the treatment of brain cancers

Martyn A. Sharpe, Daniela C. Marcano, Jacob M. Berlin, Marsha A. Widmayer, David S. Baskin, James M. Tour

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Introduced here is the hydrophilic carbon clusters (HCCs) antibody drug enhancement system (HADES), a methodology for cell-specific drug delivery. Antigen-targeted, drug-delivering nanovectors are manufactured by combining specific antibodies with drug-loaded poly(ethylene glycol)-HCCs (PEG-HCCs). We show that HADES is highly modular, as both the drug and antibody component can be varied for selective killing of a range of cultured human primary glioblastoma multiforme. Using three different chemotherapeutics and three different antibodies, without the need for covalent bonding to the nanovector, we demonstrate extreme lethality toward glioma, but minimal toxicity toward human astrocytes and neurons.

Original languageEnglish (US)
Pages (from-to)3114-3120
Number of pages7
JournalACS Nano
Issue number4
StatePublished - Apr 24 2012


  • drug delivery
  • glioblastoma multiforme
  • hydrophilic carbon clusters
  • nanovectors

ASJC Scopus subject areas

  • Engineering(all)
  • Materials Science(all)
  • Physics and Astronomy(all)


Dive into the research topics of 'Antibody-targeted nanovectors for the treatment of brain cancers'. Together they form a unique fingerprint.

Cite this